Abeona Therapeutics

📍 New York, United States🗓 Founded 2015👥 87 employees💰 Last funded Mar 2021
Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company’s multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company’s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM™ Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a novel gene-corrected cell therapy poised to enter Phase 3 in mid-2019 and complemented by one-time gene therapy candidates across four lysosomal storage diseases. Several preclinical discoveries are led by an emerging program in cystic fibrosis that uses the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases.
2
Total investors
1
Early stage
0
Mid stage
1
Late stage
2015
Founded
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Abeona Therapeutics?
Abeona Therapeutics has 2 investors on record on gritt.io, including 1 early-stage backers and 1 late-stage investors.
When did Abeona Therapeutics last raise funding?
The most recent investment in Abeona Therapeutics recorded on gritt.io was in March 2021.
When was Abeona Therapeutics founded?
Abeona Therapeutics was founded in 2015.
What industry is Abeona Therapeutics in?
Abeona Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Abeona Therapeutics based?
Abeona Therapeutics is headquartered in New York, United States.